Board and management team
Videregen is led by a successful management team experienced in medical technology translation and commercialisation, in companies ranging from start-ups to multinationals. It is advised by a Board with extensive corporate development, scientific and clinical expertise.
Dr. Steve Bloor – CEO
Steve has over 25 years’ experience in the medical device and regenerative medicine industry. He has worked in US multinationals (J&J, Covidien) and UK start-up companies, with specific expertise in leadership roles. strategic R&D, clinical compliance and regulation. Steve was formerly CSO at Tissue Science Laboratories and was behind the development of TSL’s tissue replacement technology. He subsequently became VP of R&D at Covidien following their $80m acquisition of TSL in 2008.
Doug Quinn – CFO
Doug is a chartered management accountant and experienced finance director, having spent c.20 years working with start-up and early stage technology businesses. Alongside Videregen, Doug is part-time CFO with AIM listed SkinBioTherapeutics plc.
Doug possess a wealth of experience in financial management, transactional and corporate governance, and has previously been involved in a number of M&A and AIM transactions.
Martin Hunt – Chairman
Martin has >30 years’ experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising (>£40m) in the life science sector. He is currently Programme Director of the NIHR programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board, a provider of grant funding for health research, and was previously CEO of biomaterials Company Tissue Science Laboratories plc.
Videregen is collaborating with centres of excellence to drive product research and development, including the Cell and Gene Therapy Catapult, the Royal Papworth Hospital and the Centre for Cell Gene & Tissue Therapeutics.